[CAS NO. 883986-34-3] AZD2932
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [883986-34-3]
Store
Catalog
SLK-S7003
Brand
Selleck
CAS
883986-34-3
DESCRIPTION [883986-34-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 447.49 |
| Molecular Formula | C24H25N5O4 |
| SMILES | - |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2347 mL | 11.1734 mL | 22.3469 mL |
| 5 mM | 0.4469 mL | 2.2347 mL | 4.4694 mL |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2347 mL |
| 50 mM | 0.0447 mL | 0.2235 mL | 0.4469 mL |
Description
AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with of 8 nM, 4 nM, 7 nM, and 9 nM for , , , and , respectively.
In vitro
AZD2932 effectively inhibits the activities of VEGFR-2 (IC50, 8 nM), PDGFRβ (IC50,4 nM), Flt-3 (IC50, 7 nM), and c-Kit (IC50, 9 nM). AZD2932 inhibits both PDGFRα and PDGFRβ phosphorylation with a correlation close to 1:1. AZD2932 does not inhibit the various cytochrome P450 isoforms with the worst IC50 being against 2C9 (8.0 μM). AZD2932 has no activity against hERG (IC50, 137 μM).
In vivo
In C6 rat glial tumor model, AZD2932 (p.o., b.i.d.) results in significant TGI of 64% for both 50 and 12.5 mg/kg doses. Growth of Calu-6 tumor is inhibited by 81% and 72% at 50 and 12.5 mg/kg b.i.d. (p.o.) and LoVo tumors by 67% at 50 mg/kg b.i.d (p.o.). AZD2932 (3–50 mg/kg, p.o.) causes 60–80% inhibition of both p-VEGFR-2 and p-PDGFRβ. Single bolus oral doses of AZD2932 results in dose-related inhibition of PDGFRa phosphorylation 6 h after dosing.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.